These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

591 related items for PubMed ID: 24489728

  • 1. Hypoxia increases gefitinib-resistant lung cancer stem cells through the activation of insulin-like growth factor 1 receptor.
    Murakami A, Takahashi F, Nurwidya F, Kobayashi I, Minakata K, Hashimoto M, Nara T, Kato M, Tajima K, Shimada N, Iwakami S, Moriyama M, Moriyama H, Koizumi F, Takahashi K.
    PLoS One; 2014; 9(1):e86459. PubMed ID: 24489728
    [Abstract] [Full Text] [Related]

  • 2. Oct4 plays a crucial role in the maintenance of gefitinib-resistant lung cancer stem cells.
    Kobayashi I, Takahashi F, Nurwidya F, Nara T, Hashimoto M, Murakami A, Yagishita S, Tajima K, Hidayat M, Shimada N, Suina K, Yoshioka Y, Sasaki S, Moriyama M, Moriyama H, Takahashi K.
    Biochem Biophys Res Commun; 2016 Apr 22; 473(1):125-132. PubMed ID: 26996130
    [Abstract] [Full Text] [Related]

  • 3. Role of FBXW7 in the quiescence of gefitinib-resistant lung cancer stem cells in EGFR-mutant non-small cell lung cancer.
    Hidayat M, Mitsuishi Y, Takahashi F, Tajima K, Yae T, Miyahara K, Hayakawa D, Winardi W, Ihara H, Koinuma Y, Wirawan A, Nurwidya F, Kato M, Kobayashi I, Sasaki S, Takamochi K, Hayashi T, Suehara Y, Moriyama M, Moriyama H, Habu S, Takahashi K.
    Bosn J Basic Med Sci; 2019 Nov 08; 19(4):355-367. PubMed ID: 31202256
    [Abstract] [Full Text] [Related]

  • 4. Hypoxia induces gefitinib resistance in non-small-cell lung cancer with both mutant and wild-type epidermal growth factor receptors.
    Minakata K, Takahashi F, Nara T, Hashimoto M, Tajima K, Murakami A, Nurwidya F, Yae S, Koizumi F, Moriyama H, Seyama K, Nishio K, Takahashi K.
    Cancer Sci; 2012 Nov 08; 103(11):1946-54. PubMed ID: 22863020
    [Abstract] [Full Text] [Related]

  • 5. Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer.
    Peled N, Wynes MW, Ikeda N, Ohira T, Yoshida K, Qian J, Ilouze M, Brenner R, Kato Y, Mascaux C, Hirsch FR.
    Cell Oncol (Dordr); 2013 Jul 08; 36(4):277-88. PubMed ID: 23619944
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. 1,25-dihydroxyvitamin D3 signaling-induced decreases in IRX4 inhibits NANOG-mediated cancer stem-like properties and gefitinib resistance in NSCLC cells.
    Jia Z, Zhang Y, Yan A, Wang M, Han Q, Wang K, Wang J, Qiao C, Pan Z, Chen C, Hu D, Ding X.
    Cell Death Dis; 2020 Aug 20; 11(8):670. PubMed ID: 32820157
    [Abstract] [Full Text] [Related]

  • 8. Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer.
    Jang JY, Kim YG, Nam SJ, Keam B, Kim TM, Jeon YK, Kim CW.
    Mol Cancer Ther; 2016 Jun 20; 15(6):1387-96. PubMed ID: 26883272
    [Abstract] [Full Text] [Related]

  • 9. Functional cooperation between HIF-1α and c-Jun in mediating primary and acquired resistance to gefitinib in NSCLC cells with activating mutation of EGFR.
    Meng S, Wang G, Lu Y, Fan Z.
    Lung Cancer; 2018 Jul 20; 121():82-90. PubMed ID: 29858032
    [Abstract] [Full Text] [Related]

  • 10. Treatment with insulin-like growth factor 1 receptor inhibitor reverses hypoxia-induced epithelial-mesenchymal transition in non-small cell lung cancer.
    Nurwidya F, Takahashi F, Kobayashi I, Murakami A, Kato M, Minakata K, Nara T, Hashimoto M, Yagishita S, Baskoro H, Hidayat M, Shimada N, Takahashi K.
    Biochem Biophys Res Commun; 2014 Dec 12; 455(3-4):332-8. PubMed ID: 25446090
    [Abstract] [Full Text] [Related]

  • 11. Enrichment and characterization of cancer stem cells from a human non-small cell lung cancer cell line.
    Zhao C, Setrerrahmane S, Xu H.
    Oncol Rep; 2015 Oct 12; 34(4):2126-32. PubMed ID: 26239272
    [Abstract] [Full Text] [Related]

  • 12. Reduced expression of EI24 confers resistance to gefitinib through IGF-1R signaling in PC9 NSCLC cells.
    Choi JM, Jang JY, Choi YR, Kim HR, Cho BC, Lee HW.
    Lung Cancer; 2015 Nov 12; 90(2):175-81. PubMed ID: 26342551
    [Abstract] [Full Text] [Related]

  • 13. [FOXC1 Knockdown Reverses Gefitinib Resistance in Non-small Cell Lung Cancer].
    Peng C, Li P, Yang M, Chen D, Huang Y.
    Zhongguo Fei Ai Za Zhi; 2021 Aug 20; 24(8):538-547. PubMed ID: 34334155
    [Abstract] [Full Text] [Related]

  • 14. β-Catenin overexpression is associated with gefitinib resistance in non-small cell lung cancer cells.
    Fang X, Gu P, Zhou C, Liang A, Ren S, Liu F, Zeng Y, Wu Y, Zhao Y, Huang B, Zhang Z, Yi X.
    Pulm Pharmacol Ther; 2014 Jun 20; 28(1):41-48. PubMed ID: 23707949
    [Abstract] [Full Text] [Related]

  • 15. Cucurbitacin I inhibits tumorigenic ability and enhances radiochemosensitivity in nonsmall cell lung cancer-derived CD133-positive cells.
    Hsu HS, Huang PI, Chang YL, Tzao C, Chen YW, Shih HC, Hung SC, Chen YC, Tseng LM, Chiou SH.
    Cancer; 2011 Jul 01; 117(13):2970-85. PubMed ID: 21225866
    [Abstract] [Full Text] [Related]

  • 16. All-trans retinoic acid reduces cancer stem cell-like cell-mediated resistance to gefitinib in NSCLC adenocarcinoma cells.
    Yao W, Wang L, Huang H, Li X, Wang P, Mi K, Cheng J, Liu H, Gu C, Huang L, Huang J.
    BMC Cancer; 2020 Apr 15; 20(1):315. PubMed ID: 32293355
    [Abstract] [Full Text] [Related]

  • 17. Stem cell-like ALDH(bright) cellular states in EGFR-mutant non-small cell lung cancer: a novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin.
    Corominas-Faja B, Oliveras-Ferraros C, Cuyàs E, Segura-Carretero A, Joven J, Martin-Castillo B, Barrajón-Catalán E, Micol V, Bosch-Barrera J, Menendez JA.
    Cell Cycle; 2013 Nov 01; 12(21):3390-404. PubMed ID: 24047698
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Pemetrexed induces ROS generation and cellular senescence by attenuating TS-mediated thymidylate metabolism to reverse gefitinib resistance in NSCLC.
    Chen Y, Zhang C, Jin S, Li J, Dai J, Zhang Z, Guo R.
    J Cell Mol Med; 2023 Jul 01; 27(14):2032-2044. PubMed ID: 37278440
    [Abstract] [Full Text] [Related]

  • 20. Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma.
    Hurbin A, Wislez M, Busser B, Antoine M, Tenaud C, Rabbe N, Dufort S, de Fraipont F, Moro-Sibilot D, Cadranel J, Coll JL, Brambilla E.
    J Pathol; 2011 Sep 01; 225(1):83-95. PubMed ID: 21598249
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.